- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Erschienen in
-
Peptide Receptor Radionuclide Therapy for a Phosphaturic Mesenchymal Tumor ; volume:13 ; number:3 ; year:2020 ; pages:1373-1380
Case reports in oncology ; 13, Heft 3 (2020), 1373-1380
- Urheber
-
Häfliger, Simon
Seidel, Ann-Katrin
Schoch, Eric
Reichmann, Jan
Wild, Damian
Steinmann-Schwager, Stephanie
Pless, Miklos
- DOI
-
10.1159/000510334
- URN
-
urn:nbn:de:101:1-2021011323221103441616
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
15.08.2025, 07:21 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Häfliger, Simon
- Seidel, Ann-Katrin
- Schoch, Eric
- Reichmann, Jan
- Wild, Damian
- Steinmann-Schwager, Stephanie
- Pless, Miklos
Ähnliche Objekte (12)
Peptide receptor radionuclide therapy for sarcoidosis
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy
Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy for sarcoidosis
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy
Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy somatostatin receptor-based heterogeneity predicts overall survival in pancreatic neuroendocrine tumor patients undergoing peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy for sarcoidosis
Strategies Towards Improving Clinical Outcomes of Peptide Receptor Radionuclide Therapy
Apparent pacemaker dysfunction during peptide receptor radionuclide therapy for neuroendocrine tumor
Liver-Directed Therapy for Neuroendocrine Tumor Metastases in the Era of Peptide Receptor Radionuclide Therapy
Early response assessment and prediction of overall survival after peptide receptor radionuclide therapy
Peptide receptor radionuclide therapy in patients with medullary thyroid carcinoma: predictors and pitfalls
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Prediction of clinically relevant hyperkalemia in patients treated with peptide receptor radionuclide therapy
Simplified dosimetry for kidneys and tumors in 177Lu-labeled peptide receptor radionuclide therapy
Pre-therapy Somatostatin Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy
Pre-therapy Somatostatin-Receptor-Based Heterogeneity Predicts Overall Survival in Pancreatic Neuroendocrine Tumor Patients Undergoing Peptide Receptor Radionuclide Therapy